MAM
RLAY icon

Meeder Asset Management’s Relay Therapeutics RLAY Stock Holding History

Meeder Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.3K Buy
+3,332
New +$48.4K ﹤0.01% 430

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Meeder Asset Management's RLAY Position: Q2 2026 in Review

Meeder Asset Management opened a new position in Relay Therapeutics (RLAY) in Q2 2026: 3,332 shares worth $62.3K. The stake represents ﹤0.01% of the portfolio and ranks #430 among its holdings.

258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Meeder Asset Management held 3,332 shares of Relay Therapeutics worth $62.3K as of Q2 2026.
  • Relay Therapeutics was a new Meeder Asset Management position in Q2 2026.
  • Relay Therapeutics made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #430 holding.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.